These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 18501098

  • 1. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS.
    Clin Lung Cancer; 2008 Mar; 9(2):112-5. PubMed ID: 18501098
    [Abstract] [Full Text] [Related]

  • 2. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 3. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 4. Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.
    Eser M, Kement M, Balin S, Coskun C, Kefeli U, Gumus M, Altuntas YE, Kurt N, Mayadagli A.
    World J Surg Oncol; 2012 Aug 31; 10():180. PubMed ID: 22938027
    [Abstract] [Full Text] [Related]

  • 5. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu İ, Ersoz HO.
    Endocrine; 2009 Dec 31; 36(3):473-8. PubMed ID: 19859836
    [Abstract] [Full Text] [Related]

  • 6. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep 31; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 31; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 8. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 31; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 9. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.
    Gynecol Endocrinol; 2015 Jul 31; 31(7):536-9. PubMed ID: 26220768
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 11. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct 01; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

  • 12. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
    Yüzbaşıoğlu B, Ustaoğlu M, Yüzbaşıoğlu Ş, Akbulut UE, Özdil K.
    Turk J Gastroenterol; 2019 Dec 01; 30(12):1025-1029. PubMed ID: 31854307
    [Abstract] [Full Text] [Related]

  • 13. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J, Suchowierska E, Malyszko JS, Mysliwiec M.
    Perit Dial Int; 2002 Dec 01; 22(5):582-92. PubMed ID: 12455569
    [Abstract] [Full Text] [Related]

  • 14. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
    Bouma BN, Mosnier LO.
    Pathophysiol Haemost Thromb; 2002 Dec 01; 33(5-6):375-81. PubMed ID: 15692247
    [Abstract] [Full Text] [Related]

  • 15. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct 01; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

  • 16. Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis.
    Kolasa-Trela R, Fil K, Wypasek E, Undas A.
    J Cardiol; 2015 Jun 01; 65(6):501-7. PubMed ID: 25169013
    [Abstract] [Full Text] [Related]

  • 17. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
    Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2001 Aug 01; 16(8):1692-6. PubMed ID: 11477176
    [Abstract] [Full Text] [Related]

  • 18. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan 01; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 19. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov 01; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 01; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.